Samsung Biologics Co.,Ltd. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported sales was KRW 21,963.65 million compared to KRW 16,220.43 million a year ago. Net income was KRW 131,773.53 million compared to KRW 56,081.37 million a year ago. Basic earnings per share from continuing operations was KRW 1,992 compared to KRW 848 a year ago. Basic earnings per share was KRW 1,992 compared to KRW 848 a year ago. For the nine months, sales was KRW 86,071.38 million compared to KRW 32,932.84 million a year ago. Net income was KRW 314,271.53 million compared to KRW 144,753.07 million a year ago. Basic earnings per share from continuing operations was KRW 4,750 compared to KRW 2,188 a year ago. Basic earnings per share was KRW 4,750 compared to KRW 2,188 a year ago.